Toronto, Canada (PRWEB) September 24, 2012
It is estimated that only 1 out of every 1,000 preclinical candidates reaches the commercial market. The ability to assess the “developability” of a therapeutic candidate in early preclinical and clinical phases of development can be a very powerful tool to enhance the chance of success. This webinar will discuss a number of methodologies to facilitate the assessment of potential development risks including safety and immunogenicity, stability, aggregation, and low productivity. For more information or to register go to http://xtks.in/xto-513
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx
Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com